These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029 [TBL] [Abstract][Full Text] [Related]
31. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600 [TBL] [Abstract][Full Text] [Related]
32. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626 [TBL] [Abstract][Full Text] [Related]
33. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265 [TBL] [Abstract][Full Text] [Related]
34. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161 [TBL] [Abstract][Full Text] [Related]
35. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317 [TBL] [Abstract][Full Text] [Related]
36. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Argiris A; Seropian S; Cooper DL Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053 [TBL] [Abstract][Full Text] [Related]
37. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160 [TBL] [Abstract][Full Text] [Related]
38. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155 [TBL] [Abstract][Full Text] [Related]
39. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. Sapelli J; Filho JS; Matias Vieira GM; Moura FL; Germano JN; de Lima VCC Leuk Res; 2021 Nov; 110():106689. PubMed ID: 34592699 [TBL] [Abstract][Full Text] [Related]
40. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]